Methapharm
Methapharm is a Canadian specialty pharmaceutical company that acquires, licenses, and distributes prescription drugs and medical devices across North America. It serves healthcare professionals, hospitals, and pharmacies through exclusive distribution agreements with global pharmaceutical manufacturers including Chiesi, Bayer, Guerbet, and Bosch Healthcare.
- Company typePrivate
- Founded1996
- HeadquartersBrantford, Canada
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Methapharm does
Methapharm Inc. (operating as Methapharm Specialty Pharmaceuticals) is a privately held Canadian specialty pharmaceutical company focused on the acquisition, licensing, distribution, and promotion of prescription drugs and medical devices in North America. Founded in 1996 and headquartered in Mississauga, Ontario, the company sources products from global pharmaceutical manufacturers and serves healthcare professionals, hospitals, and pharmacies across Canada and the United States, with a European affiliate office in Dublin, Ireland. Its go-to-market combines exclusive territorial distribution agreements (Canadian distributor for Chiesi, Bayer, SERB SA, Adienne products; US marketer/distributor for VVT Medical, Bosch Healthcare devices) with promotion through industry conferences and direct engagement with healthcare practitioners.
Methapharm's portfolio spans four therapeutic segments: respiratory diagnostics (the proprietary Provocholine trademark, plus licensed Aridol and Curosurf); hospital and acute care products (Cleviprex, Cyanokit, Kengrexal, Peyona, Custodiol HTK, Tepadina, Erythrocin, Fucithalmic); diagnostic imaging (Guerbet contrast agents Optiray, Dotarem, Lipiodol, and power injectors IllumenaNeo, OptiStar Elite, OptiVantage, plus Vivatmo pro FeNO device); and pharmacy-dispensed specialty medications (Androcur, Resotran, Salagen, Xermelo, Asclera). Provocholine is the company's only proprietary product; the remainder consists of in-licensed or distributed third-party brands.
Methapharm generates revenue primarily through distribution margins and licensing/promotion arrangements with global pharmaceutical manufacturers. It holds VAWD accreditation from NABP (since October 2007), operates an FDA-regulated US distribution operation out of Boca Raton, Florida, and has passed State of Florida pharmaceutical inspections. The company is independently owned with no disclosed institutional investors or external funding rounds, and has maintained continuous partnership-driven growth since at least 2004, with a sustained cadence of new product additions through 2025.
Methapharm firmographics
Firmographics- Name
- Methapharm
- Legal name
- Methapharm Inc.
- Website
- https://methapharm.com
- Company type
- Private
- Founded year
- 1996
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Methapharm is a Canadian specialty pharmaceutical company that acquires, licenses, and distributes prescription drugs and medical devices across North America. It serves healthcare professionals, hospitals, and pharmacies through exclusive distribution agreements with global pharmaceutical manufacturers including Chiesi, Bayer, Guerbet, and Bosch Healthcare.
- Ownership category
- akta.pro rank
Methapharm industry classification
Industry- Product category
- Specialty Pharmaceuticals
- NAICS
- Drugs and Druggists' Sundries Merchant Wholesalers (42421), Drugs and Druggists' Sundries Merchant Wholesalers (424210), Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where Methapharm is headquartered
LocationHeadquarters
- HQ city
- Brantford
- HQ country
- Canada
- HQ region
- North America
Offices3 records
Markets served
Methapharm business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Marketing or Sales, Personnel, Operations, Others
Revenue model
- Pharmaceutical Distribution: Distribution of specialty pharmaceutical products across North America, acting as Canadian and US distributor for various international pharmaceutical brands.
- Product Licensing and Promotion: Acquisition, licensing, and promotion of specialty pharmaceutical products, marketing proprietary products and partnering with global companies for prescription drug products in USA and Canada.
- Diagnostic Products Distribution: Distribution of diagnostic products including respiratory diagnostics (Aridol, Provocholine), imaging contrast agents, and medical devices like Vivatmo pro and ScleroSafe.
Go-to-market motion2 records
Distribution channels3 records
Marketing channels3 records
Methapharm product offering
Product offeringCore offering
Methapharm is a specialty pharmaceutical company that focuses on the acquisition, licensing, partnering, and promotion of specialty pharmaceutical products in North America. The company markets its own proprietary product (Provocholine) and acts as the exclusive Canadian or US distributor and promoter for numerous international pharmaceutical brands spanning respiratory diagnostics, hospital/acute care injectables, contrast imaging agents and devices, and pharmacy-dispensed specialty medications.
Product overview
Methapharm is a specialty pharmaceutical company that operates as a product portfolio rather than a unified software platform. The company focuses on development, acquisition, licensing, and promotion of specialty healthcare products in North America. The portfolio comprises three main categories: (1) Proprietary and distributed respiratory products including Provocholine (methacholine chloride) for bronchial challenge testing, Aridol (mannitol inhalation powder), and Curosurf (poractant alfa) for neonatal RDS; (2) Hospital and acute care products including Cleviprex (clevidipine), Cyanokit (hydroxocobalamin), Kengrexal (cangrelor), Peyona (caffeine citrate), and Custodiol HTK for organ preservation; (3) Diagnostic imaging products including Guerbet contrast agents (Optiray, Dotarem, Lipiodol), contrast delivery injectors (IllumenaNeo, OptiStar Elite, OptiVantage), and FeNO devices (Vivatmo pro); and (4) Additional specialty pharmaceuticals including Androcur, Salagen, Resotran, Xermelo, Asclera, and urology products (Fluidrain, UroDrain). Methapharm functions primarily as a distributor and commercial partner, bringing international pharmaceutical products to the Canadian and US markets through licensing and distribution agreements.
Differentiator
Problem solved
Functional benefit
Products and services
- Provocholine (methacholine chloride USP) Methacholine chloride powder for solution used by healthcare professionals for diagnosis of bronchial hyperresponsiveness in subjects without clinically detectable asthma. Proprietary brand of Methapharm Inc.
- Aridol (mannitol inhalation powder) Mannitol inhalation powder for bronchial challenge testing to assess bronchial hyperresponsiveness in patients without clinically detectable asthma.
- Curosurf (poractant alfa) Surfactant indicated for the treatment of respiratory distress syndrome (RDS) in premature infants.
- Cleviprex (clevidipine injection) Injectable emulsion indicated for the management of acute elevation of blood pressure in perioperative settings.
- Cyanokit (hydroxocobalamin) Antidote indicated for the treatment of known or suspected cyanide poisoning.
- Kengrexal (cangrelor) Direct P2Y12 platelet receptor inhibitor that blocks ADP-induced platelet activation and aggregation.
- Peyona (Caffeine Citrate Injection and Oral Solution) Caffeine citrate for use in Neonatal Intensive Care Units for treatment of apnea of prematurity.
- Custodiol HTK (Histidine-Tryptophan-Ketoglutarate) Solution for preservation of multi-organ transplants (heart, kidneys, liver, pancreas, lungs) along with venous or arterial segments.
- Androcur (cyproterone acetate tablets) Oral tablets indicated for palliative treatment of patients with advanced prostatic carcinoma.
- Asclera (polidocanol) Injection
Companies that use Methapharm
Customer profileSegments5 records
Ideal customer profiles4 records
Methapharm technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Methapharm partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and minor.
- Bayer (ANDROCUR)coreMethapharm appointed as Canadian distributor for ANDROCUR (cyproterone) tablets, supplying pharmacies across Canada.
- Bosch Healthcare Solutions GmbHcoreMethapharm appointed as distributor of Vivatmo Pro, the newest FDA-Cleared FeNO device, in the United States.
- VVT Medical Ltd.coreVVT Medical Ltd. appoints Methapharm as Distributor of ScleroSafe in the US.
- Chiesi (KENGREXAL)coreMethapharm appointed as Canadian distributor for KENGREXAL (cangrelor).
- Chiesi (RESOTRAN)coreMethapharm appointed as Canadian distributor for RESOTRAN (prucalopride).
- Chiesi (CLEVIPREX)coreCHIESI appoints Methapharm as Canadian Distributor for CLEVIPREX (clevidipine).
- BAYER (ASCLERA)coreMethapharm appointed US marketer for ASCLERA (polidocanol) injection.
- GuerbetcoreGuerbet, global specialist in contrast agents and solutions for medical imaging, announced that Methapharm will promote and distribute all Guerbet products in Canada.
- US Partnership for Sterile Methacholine SolutionsminorNew partnership to offer ready-to-use sterile methacholine solution kits.
- Biointerfaces Institute of McMaster UniversityminorMethapharm announces development agreement with Biointerfaces Institute of McMaster University for R&D investment.
- Adienne SA (TEPADINA)coreAdienne SA appoints Methapharm as Canadian distributor for TEPADINA (Thiotepa for injection, BP).
- SERB SA (CYANOKIT)coreSERB SA appoints Methapharm as Canadian distributor for CYANOKIT (hydroxocobalamin).
Scale indicators2 records
Recent moves9 records
Expansion highlights4 records
Methapharm competitors and assessment
Company assessmentDirect peers
- Verity Pharmaceuticals: Canadian specialty pharmaceutical company focused on licensing and commercialization of women's health and specialty products in North America, operating a comparable appointed-distributor business model.
- Medison Pharma: Global specialty pharmaceutical distributor focused on licensing and commercializing niche specialty therapies across multiple geographies, with comparable multi-territory appointed-distributor arrangements.
- Paladin Labs: Canadian specialty pharmaceutical acquirer and distributor (now an Endo International subsidiary) historically built on licensing specialty brands for the Canadian market, closely mirroring Methapharm's commercial model.
- Sterimax Inc. Canadian specialty pharmaceutical company that in-licenses, distributes, and markets specialty injectable and hospital products in Canada, overlapping with Methapharm's hospital segment.
- Cipher Pharmaceuticals: Canadian-listed specialty pharmaceutical company that acquires, licenses, and distributes branded specialty products across North America, with a portfolio model structurally similar to Methapharm's licensing-and-distribution approach.
Others
- Innomar Strategies (Cencora): Canadian specialty pharmaceutical distribution and patient support services provider (now part of Cencora/AmerisourceBergen) operating in the same specialty pharma commercialization ecosystem as Methapharm.
Regional players
- AA Pharma: Canadian specialty pharmaceutical company distributing branded prescription products through pharmacy channels, structurally similar to Methapharm's pharmacy segment focus on Canadian retail distribution.
Broad incumbents
- Endo International: Specialty pharmaceutical company with a portfolio spanning branded specialty, injectables, and sterile products through Paladin Labs (Canada), overlapping with Methapharm's hospital and specialty distribution footprint.
- Mallinckrodt plc: Specialty pharmaceutical company with hospital injectables, contrast imaging, and rare disease franchises; competes with Methapharm in the specialty injectable and imaging contrast segments at a much larger scale.
- Bausch Health Companies: Large Canadian-headquartered specialty pharmaceutical company with broad branded specialty, hospital, and neurology franchises; operates a much wider portfolio but competes in the same specialty-pharma distribution dynamics.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights7 records
Customer concentration
Methapharm social profiles
Digital presenceMethapharm compliance and trust
Trust signalCompliance2 records
Methapharm financial estimates
Financial estimateRevenue estimate
Valuation estimate
Methapharm leadership team
Management profileNumber of profiles
Profiles1 record
Methapharm funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Methapharm M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Methapharm
What does Methapharm do?
Methapharm is a specialty pharmaceutical company that focuses on the acquisition, licensing, partnering, and promotion of specialty pharmaceutical products in North America. The company markets its own proprietary product (Provocholine) and acts as the exclusive Canadian or US distributor and promoter for numerous international pharmaceutical brands spanning respiratory diagnostics, hospital/acute care injectables, contrast imaging agents and devices, and pharmacy-dispensed specialty medications.
Is Methapharm a public or private company?
Methapharm is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Methapharm founded?
Methapharm was founded in 1996. It employs 51 to 100 people.
Where is Methapharm based?
Methapharm is headquartered in Brantford, Canada, in the North America region.
How does Methapharm make money?
Three revenue lines are on record. Pharmaceutical Distribution is the primary driver. The others are product Licensing and Promotion and diagnostic Products Distribution.
Who are Methapharm's main competitors?
Direct peers on record are Verity Pharmaceuticals, Medison Pharma, Paladin Labs, Sterimax Inc. and Cipher Pharmaceuticals. Innomar Strategies (Cencora) is listed as an others. AA Pharma is listed as a regional player. Broad incumbents are Endo International, Mallinckrodt plc and Bausch Health Companies.
Does Methapharm have an API?
No public API is recorded for Methapharm.
What industry is Methapharm in?
Methapharm's product category is Specialty Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 42421 and its SIC code is 5122.